Enas Kamal

Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C‐related cirrhosis, genotype 4

Hisham R El‐Khayat, Yasser Fouad, Hala Mohamed et al. · Alimentary Pharmacology & Therapeutics · 2018 · 48 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Yasser Fouad, Gamal Esmat, Reda Elwakil et al. · Saudi Journal of Gastroenterology · 2022 · 46 citations · Full text

Medicine, Internal Medicine, Gastroenterology +13

The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real‐world experience

Hisham R El‐Khayat, Enas Kamal, Manal H. El‐Sayed et al. · Alimentary Pharmacology & Therapeutics · 2018 · 45 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6‐ to 12‐ year old children

Mortada El‐Shabrawi, Naglaa M. Kamal, Hisham R El‐Khayat et al. · Alimentary Pharmacology & Therapeutics · 2018 · 27 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +17

Clinical significance and diagnostic value of serum dickkopf-1 in patients with hepatocellular carcinoma

Yasser Fouad, Hala Mohamed, Enas Kamal et al. · Scandinavian Journal of Gastroenterology · 2016 · 21 citations · Full text

Medicine, Oncology, Pathology +17